Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Intercept’s fatty liver drug meets late-stage main goal

Intercept Pharmaceuticals Inc. said the treatment obeticholic acid (OCA) showed an improvement in scarring on the organ in patients with a progressive fatty liver disease.

Read More »

Pfizer-Lilly drug shown to help reduce back pain in late-stage trial

A non-opioid painkiller developed by Pfizer Inc. and Eli Lilly and Co. succeeded in reducing chronic low back pain when used in a stronger dose, results from a late-stage study showed.

Read More »

Interval training burns off more pounds than jogging or cycling

Workouts that mix up a variety of intense exercises with brief recovery periods in between may help people lose more weight than chugging along at a steady pace on a treadmill or exercise bike, a research review suggests.

Read More »

Japan approves test of iPS cells for spinal injuries

Japanese scientists will test the use of human-induced pluripotent stem cells (iPS) to treat spinal cord injuries, a health ministry panel that approved the research project said.

Read More »

New Test Measures Pain Levels Using Biomarkers in the Blood

As the United States continues to grapple with the opioid epidemic, researchers have developed a new test that can measure pain biomarkers in the blood.

Read More »

Keytruda In Combination With Inlyta Reduced Risk Of Death By Nearly Half Compared To Sunitinib As First-Line Treatment For Advanced RCC

Merck & Co. announced presentation of the full results from the pivotal Phase 3 KEYNOTE-426 trial investigating the company’s anti-PD-1 therapy Keytruda in combination with Inlyta, a tyrosine kinase inhibitor, for the first-line treatment of advanced renal cell carcinoma (RCC) at the 2019 Genitourinary Cancers Symposium.

Read More »

Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients

Nektar Therapeutics said some patients with advanced bladder cancer treated with a combination of the company’s experimental treatment and Bristol-Myers Squibb’s immunotherapy Opdivo showed signs of tumor reduction in an early-stage study.

Read More »

Leaving the hospital early can double the odds of going back

Patients who discharge themselves from the hospital against medical advice are twice as likely to be back within 30 days as those who leave when doctors say they are ready, a large U.S. study finds.

Read More »

Push-up capacity may predict men’s heart disease risk

The number of push-ups a man can do in the doctor’s office may be a good predictor of his risk of developing heart disease in the coming years, new research suggests.

Read More »

Antipsychotic Rexulti Fails Two Bipolar Phase III Trials

Denmark’s H. Lundbeck and Japan’s Otsuka Pharmaceutical announced that the antipsychotic drug Rexulti (brexpiprazole) failed to meet the primary endpoint in two Phase III clinical studies to treat manic episodes in patients with bipolar I disorder.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom